Genmab — Januar 2019
-
Det giver 3,5 mia $ for 2019.
-
Hvis din teori holder stik..Bulder
-
Tror du de tør?
-
Der kan vel også blive noget med rabater i 2019?
-
Det må vi da håbe de har.
-
Han kunne jo også lave noget elastik...3-3,5?
-
Så ville det være noget nemmere at ramme indenfor skiven.
-
hold da op - der var nogen, der ville være med I slutauktionen!
-
Nå den fik lidt i luk...kun n
ede 3,4% -
GENMAB A/S: GENMAB ANNOUNCES INITIATION OF U.S. FDA REGULATORY SUBMISSION FOR LABEL EXPANSION OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXA
16:57
Company Announcement- First part of regulatory package submitted to the U.S. FDA for label
expansion of daratumumab in combination with lenalidomide and
dexamethasone for patients with newly diagnosed multiple myeloma who
are not candidates for high dose chemotherapy and autologous stem
cell transplant - The U.S. FDA plan to review th
- First part of regulatory package submitted to the U.S. FDA for label
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind